Real-world evidence (RWE) services in Europe — the observational studies, patient registry programs, database studies, and post-authorization safety studies (PASS) generating evidence from routine clinical practice — create the growing European CRO market beyond traditional interventional clinical trials, with the Europe CRO Market reflecting RWE as an increasingly important commercial service area.

European patient registry infrastructure — the remarkable European health registry ecosystem (Nordic countries' universal registries, UK Biobank, French SNDS national health data system, German GePaRD prescription database) providing the data infrastructure for real-world evidence generation. These registries' decades of longitudinal patient data combined with linkage capabilities enabling powerful population-based observational studies.

EMA RWE framework — the EMA's Real-World Evidence Framework and the EU RWE collaboration platform establishing the regulatory pathway for RWE submissions supporting regulatory decisions (extensions of indication, label modifications, PASS requirements). The growing EMA acceptance of RWE for specific regulatory applications creating the commercial demand for EMA-ready RWE study design and conduct.

PASS (Post-Authorization Safety Studies) requirement — the EMA requirement for PASS as conditions of marketing authorization for many medicines in Europe — creating the mandated RWE service market. CROs conducting PASS studies must navigate the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) registry requirements and PASS protocol transparency obligations.

Do you think European health data infrastructure will become a global competitive advantage for generating real-world evidence, making European CROs the preferred partners for RWE generation globally?

FAQ

What makes European health data infrastructure valuable for RWE? European RWE advantages: Nordic universal health registries (Denmark, Sweden, Finland, Norway — near-complete population coverage, decades of longitudinal data, high data quality); UK CPRD (Clinical Practice Research Datalink) — primary care records for seventy-plus million patients; French SNDS (Système National des Données de Santé) — universal health data linkage; Spanish regional databases (SIDIAP, BIFAP); Dutch PHARMO; EUCRN cancer registry network; linkage across registries (prescription, hospitalization, death records); GDPR compliance demonstrating data governance; ENCePP pre-registration of pharmacoepidemiology studies; combined: most powerful population-level RWE infrastructure globally.

What is a PASS and when does EMA require it? PASS (Post-Authorization Safety Study): EMA condition of approval for medicines with specific safety concerns; required to monitor specific identified or potential risks in real-world practice; types: non-interventional (observational, registry-based, database studies) or interventional; PASS protocol subject to EMA/PRAC scrutiny; registered in ENCePP registry for transparency; results submitted to EMA with defined milestones; failure to complete PASS: potential marketing authorization suspension; PASS creation market: EMA estimates thousands of PASS obligations for EU-authorized medicines; significant CRO service market from mandatory compliance requirement.

#EuropeCRO #RealWorldEvidence #EuropeanRWE #PASS #EMAevidence #EuropeHealthData